货号:A121952 同义名: 表儿茶素;表儿茶精 / (-)-Epicatechol;NSC 81161
(-)-Epicatechin is a polyphenolic flavonoid that can act as an inhibitor of COX-1 (IC50 = 3.2 μM) and has activities of antioxidant, lipid-lowering and hypoglycemic, prevent cardiovascular diseases. (−)-Epicatechin is a 2R,3R stereoisomer of catechin.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | COX ↓ ↑ | COX-1 ↓ ↑ | COX-2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Piroxicam | ✔ | 98% | |||||||||||||||||
Salicylic acid | ✔ | 98% | |||||||||||||||||
Phenacetin | ✔ | 98% | |||||||||||||||||
Etodolac | ✔ | 99% | |||||||||||||||||
Flunixin meglumine | ✔ | 98% | |||||||||||||||||
Ibuprofen L-lysine | ✔ | 99% | |||||||||||||||||
Nabumetone | ✔ | 98% | |||||||||||||||||
Acemetacin | ✔ | 98% | |||||||||||||||||
Diflunisal | ✔ | 98% | |||||||||||||||||
Pranoprofen | ✔ | 98% | |||||||||||||||||
Ampiroxicam | ✔ | 98% | |||||||||||||||||
Meloxicam | ✔ | 98% | |||||||||||||||||
Sulindac | ✔ | 98% | |||||||||||||||||
Ketoprofen | ✔ | 98% | |||||||||||||||||
Mefenamic Acid | ✔ | 95% | |||||||||||||||||
Bromfenac sodium | ✔ | 98% | |||||||||||||||||
Oxaprozin | ✔ | 99% | |||||||||||||||||
Aspirin | ✔ | 99% | |||||||||||||||||
Nepafenac | ✔ | 98% | |||||||||||||||||
Zaltoprofen | ✔ | 99% | |||||||||||||||||
Salicin | ✔ | 98% | |||||||||||||||||
Suprofen | ✔ | 99%+ | |||||||||||||||||
Xanthohumol | ✔ | 99% | |||||||||||||||||
Parecoxib | ✔ | 98% | |||||||||||||||||
Tolfenamic Acid |
+++
COX-2, IC50: 0.2 μM |
98% | |||||||||||||||||
Etoricoxib | ✔ | 99% | |||||||||||||||||
Niflumic Acid | ✔ | 98% | |||||||||||||||||
Valdecoxib |
++++
COX-2, IC50: 5 nM |
99+% | |||||||||||||||||
Ibuprofen |
+
COX-1, IC50: 13 μM |
+
COX-2, IC50: 370 μM |
98% | ||||||||||||||||
Indomethacin |
++
COX1, IC50: 0.28 μM |
+
COX-2, IC50: 14 μM |
97% | ||||||||||||||||
Lornoxicam |
++++
COX-1, IC50: 5 nM |
++++
COX-2, IC50: 8 nM |
98% | ||||||||||||||||
Meclofenamic acid sodium |
++++
COX-1, IC50: 40 nM |
+++
COX-2, IC50: 50 nM |
99% | ||||||||||||||||
Rofecoxib |
++++
COX-2, IC50: 18 nM |
98% | |||||||||||||||||
Asaraldehyde | ✔ | 98% | |||||||||||||||||
Naproxen |
+
COX-1, IC50: 8.7 μM |
+
COX-2, IC50: 5.2 μM |
98% | ||||||||||||||||
Diclofenac Sodium Salt |
+++
COX-1, IC50: 60 nM |
+++
COX-2, IC50: 200 nM |
98% | ||||||||||||||||
NS-398 |
++
COX-2, IC50: 3.8 μM |
98% | |||||||||||||||||
Amfenac Sodium Hydrate |
++
COX-1, IC50: 250 nM |
+++
COX-2, IC50: 150 nM |
98%+ | ||||||||||||||||
Nimesulide |
+
COX-2, IC50: 26 μM |
98% | |||||||||||||||||
Lumiracoxib |
++
COX-1, Ki: 3 μM |
+++
COX-2, Ki: 60 nM |
98% | ||||||||||||||||
Rutaecarpine | ✔ | 95% | |||||||||||||||||
Celecoxib |
++++
COX-2, IC50: 40 nM |
98% | |||||||||||||||||
Carprofen |
++++
canine COX2, IC50: 30 nM |
98% | |||||||||||||||||
Ketorolac |
++
COX-1 (human), IC50: 1.23 μM |
++
COX-2 (human), IC50: 3.50 μM |
98% | ||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
描述 | (−)-Epicatechin, as a flavanols, is found as a natural product in cacao and cacao products, such as dark chocolate, and in green tea. (−)-Epicatechin potently reduced luciferase expression (EC50 of 20.5 nM) at 6 hours. Neurons were treated with (−)-epicatechin (100 nM for 6 hours), (−)-Epicatechin decreased Aβ1-40 levels by approximately 30%[3]. In vivo, high-flavonoid dark chocolate containing 46 mg (−)-epicatechin daily for 2 weeks showed superior vascular function as seen by improved endothelium-dependent flow-mediated dilation of the brachial artery. Moreover, a reduction in ovalbumin-specific IgE present in the mice fed with the high dose (26 ± 13 ng/mL) and medium dose (89 ± 35 ng/mL) of (−)-epicatechin [4]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT01360320 | Colorectal Serrated Adenomas ... 展开 >> Colorectal Tubular Adenomas Colorectal Villous Adenomas Colorectal Tubulovillous Adenomas 收起 << | Phase 2 | Unknown | March 2018 | Germany ... 展开 >> Ostalb-Klinikum Aalen, Medizinische Klinik 1, Sekretariat Prof. Kleber Recruiting Aalen, Germany, 73430 Contact: Caroline Walny caroline.walny@ostalb-klinikum.de Principal Investigator: Gerhard Kleber, MD Klinikum Altenburger Land, Gastroenterologie Not yet recruiting Altenburg, Germany, 04600 Contact: Michael Repp, MD michael.repp@klinikum-altenburgerland.de Principal Investigator: Michael Repp, MD Klinikum Augsburg, III. Med. Klinik Recruiting Augsburg, Germany, 86156 Contact: Tanja Hilmer Tanja.Hilmer@klinikum-augsburg.de Krankenhaus Bietigheim-Bissingen, Klinik für Innere Medizin, Gastroenterologie, Hämato-Onkologie Recruiting Bietigheim-Bissingen, Germany, 74321 Contact: Ulla Hegmann hegmul01@kliniken-lb.de Principal Investigator: Siegfried Walker, MD Krankenhaus Buchholz, Abteilung Innere Medizin Recruiting Buchholz, Germany, 21244 Contact: Dirk Fahrenholz, MD Dirk.Fahrenholz@krankenhaus-buchholz.de Principal Investigator: Dirk Fahrenholz, MD Kliniken der Stadt Köln gGmbH, Krankenhaus Holweide -Medizinische Klinik- Recruiting Cologne, Germany Contact: Claudia Kaiser-Stolz Kaiser-Stolz@kliniken-koeln.de Principal Investigator: Ulrich Huegle, MD Klinikum Esslingen, Klinik für Innere Medizin, Onkologie, Gastroenterologie Recruiting Esslingen, Germany, 73730 Contact: Stephanie Klink s.klink@kliniken-es.de Principal Investigator: Michael Geissler, MD Universitätsklinikum der Ernst-Moritz-Arndt-Universität Greifswald, Klinik und Poliklinik für Innere Medizin A Recruiting Greifswald, Germany, 17475 Contact: Eckhard Weber eckhard.weber@uni-greifswald.de Principal Investigator: Julia Mayerle, MD Dr. Zeisler, Praxis für Innere Medizin und Gastroenterologie Recruiting Halle, Germany, 06108 Contact: Brigitte Schneider gastrozeisler@yahoo.de Principal Investigator: Thomas Zeisler, MD Dres. Fechner/Behrens/Steudel - Gastroenterologisch-Onkologische Praxisklinik Recruiting Halle, Germany, 06108 Contact: Anja Schlenk bsf@gastro-halle.de Principal Investigator: Ruediger Behrens, MD Dr. Frank-Gleich Praxis für Innere Medizin und Gastroenterologie Recruiting Halle, Germany, 06110 Contact: Ute Kabisch u.kabisch@onkomedic.de Principal Investigator: Stefanie Frank-Gleich, MD Universitätsklinikum Halle, Klinik für Innere Medizin I Recruiting Halle, Germany, 06120 Contact: Teuber Evelin evelin.teuber@medizin.uni-halle.de Principal Investigator: Thomas Seufferlein, MD Sub-Investigator: Thomas J. Ettrich, MD Klinikum Ludwigsburg, Medizinische Klinik I Recruiting Ludwigsburg, Germany, 71640 Contact: Samuel Raad samuel.raad@kliniken-lb.de Principal Investigator: Karel Caca, MD Diakoniekrankenhaus Mannheim, Medizinische Klinik II Recruiting Mannheim, Germany, 68163 Contact: Ulrich Damian, MD u.damian@diako-ma.de Principal Investigator: Ulrich Damian, MD II. Medizinische Klinik und Poliklinik der TU München, Klinikum rechts der Isar Recruiting Munich, Germany, 81675 Contact: Jens Zimmermann Studiensekretariat.med2@lrz.tum.de Principal Investigator: Jens T. Siveke, MD Klinik Mühldorf Abt.Gastroenterologie Recruiting Mühldorf am Inn, Germany, 84453 Contact: Melanie Mühlberger melanie.muehlberger@kliniken-muehldorf.de Principal Investigator: Gerhard Fuechsl, MD Klinikum Bogenhausen, Interdisziplinäre Onkologische Tagklinik Recruiting München, Germany, 81525 Contact: Romy Petermann romy.petermann@klinikum-muenchen.de Principal Investigator: Martin Fuchs, MD Regio Kliniken Pinneberg Not yet recruiting Pinneberg, Germany, 25421 Contact: Stefan Tardos, MD stefan.tardos@regiokliniken.de Principal Investigator: Stefan Tardos, MD Klinikum St. Elisabeth, I. Medizinische Klinik Recruiting Straubing, Germany, 94315 Contact: Stefanie Wolf stefanie.wolf@klinikum-straubing.de Principal Investigator: Weigert Norbert, MD Universitätsklinikum Ulm, Klinik für Innere Medizin I Recruiting Ulm, Germany, 89081 Contact: Yvonne Kriebisch yvonne.kriebisch@uniklinik-ulm.de Principal Investigator: Goetz von Wichert, MD Evangelisches Krankenhaus Wesel, Abteilung Innere Medizin Recruiting Wesel, Germany, 46485 Contact: Adelheid Rosendahl rosendahl@evkwesel.de Principal Investigator: Dirk Hartnack, MD 收起 << |
NCT02447783 | Healthy | Not Applicable | Completed | - | United States, California ... 展开 >> Ragle Human Nutrition Research Center, Department of Nutrition at UC Davis Davis, California, United States, 95616 收起 << |
NCT02422745 | Cardiovascular Disease ... 展开 >> Cancer 收起 << | Phase 4 | Active, not recruiting | October 2020 | United States, Massachusetts ... 展开 >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02215 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109 收起 << |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.45mL 0.69mL 0.34mL |
17.23mL 3.45mL 1.72mL |
34.45mL 6.89mL 3.45mL |
CAS号 | 490-46-0 |
分子式 | C15H14O6 |
分子量 | 290.268 |
别名 | 表儿茶素;表儿茶精 ;(-)-Epicatechol;NSC 81161;l-Epicatechol;l-Acacatechin;(2R,3R)-(-)-Epicatechin;Epicatechol;(−)-Epicatechin;L-Epicatechin;Epicatechin |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Sealed in dry,2-8°C |
溶解度 |
DMSO: 105 mg/mL(361.73 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 2 mg/mL(6.89 mM),配合低频超声,并水浴加热至45℃助溶 |
动物实验配方 |